Cargando…

Targeting KRAS in Pancreatic Cancer

Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cowzer, Darren, Zameer, Mohammed, Conroy, Michael, Kolch, Walter, Duffy, Austin G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692903/ https://www.ncbi.nlm.nih.gov/pubmed/36579598 http://dx.doi.org/10.3390/jpm12111870

Ejemplares similares

Emerging RAS-directed therapies for cancer
por: Conroy, Michael, et al.
Publicado: (2021)

Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
por: Nollmann, Friederike Inga, et al.
Publicado: (2020)

Advanced Bile Duct Cancers: A Focused Review on Current and Emerging Systemic Treatments
por: Cowzer, Darren, et al.
Publicado: (2022)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

Therapeutic Targets of KRAS in Colorectal Cancer
por: Rahman, Shafia, et al.
Publicado: (2021)

Acrometastasis as the Initial Presentation of a KRAS-Positive Colon Cancer
por: Gharwan, Helen, et al.
Publicado: (2012)

Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
por: Lee, Shannon, et al.
Publicado: (2020)

Oncogenic KRAS signalling in pancreatic cancer
por: Eser, S, et al.
Publicado: (2014)

Kras as a key oncogene and therapeutic target in pancreatic cancer
por: Collins, Meredith A., et al.
Publicado: (2014)

Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer
por: Kamerkar, Sushrut, et al.
Publicado: (2017)

Targeting the untargetable KRAS in cancer therapy
por: Liu, Pingyu, et al.
Publicado: (2019)

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
por: Zeitouni, Daniel, et al.
Publicado: (2016)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

Clinical Utility of (18)F-2-Fluoro-deoxy-d-glucose PET Imaging in Locally Advanced Esophageal/Gastroesophageal Junction Adenocarcinoma
por: Cowzer, Darren, et al.
Publicado: (2023)

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
por: Gillson, Josef, et al.
Publicado: (2020)

Targeting KRAS in Cancer: Promising Therapeutic Strategies
por: Mustachio, Lisa Maria, et al.
Publicado: (2021)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
por: Grinshpun, Albert, et al.
Publicado: (2019)

Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail
por: Elhariri, Ahmed, et al.
Publicado: (2023)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
por: Luo, Yongde, et al.
Publicado: (2021)

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
por: Zhang, Joshua, et al.
Publicado: (2023)

KRAS: A Druggable Target in Colon Cancer Patients
por: Negri, Francesca, et al.
Publicado: (2022)

RASSF1A Tumour Suppressor: Target the Network for Effective Cancer Therapy
por: García-Gutiérrez, Lucía, et al.
Publicado: (2020)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

Beyond Kras: MYC Rules in Pancreatic Cancer
por: Korc, Murray
Publicado: (2018)

Zebrafish model of KRAS-initiated pancreatic cancer
por: Park, Joon Tae, et al.
Publicado: (2018)

KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer
por: Dai, Manxiong, et al.
Publicado: (2022)

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib
por: Nolan, Aoife, et al.
Publicado: (2023)

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
por: Indini, Alice, et al.
Publicado: (2021)

Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma
por: Hafezi, Shirin, et al.
Publicado: (2021)

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
por: Golan, Talia, et al.
Publicado: (2015)

Targeting KRAS mutant lung cancer: light at the end of the tunnel
por: Drosten, Matthias, et al.
Publicado: (2022)

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
por: Hyun, Soonsil, et al.
Publicado: (2021)

Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
por: Sunaga, Noriaki, et al.
Publicado: (2021)

Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
por: Bteich, Fernand, et al.
Publicado: (2023)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
por: Collins, Meredith A., et al.
Publicado: (2012)

Survival of pancreatic cancer cells lacking KRAS function
por: Muzumdar, Mandar Deepak, et al.
Publicado: (2017)

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
por: Liu, Yu-Huei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5srq98cuc1eanehm6qeu18rnep